Cargando…
Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170321/ https://www.ncbi.nlm.nih.gov/pubmed/34104219 http://dx.doi.org/10.1177/17562864211019567 |
| _version_ | 1783702217528705024 |
|---|---|
| author | Piquet, Amanda L. Corboy, John R. Vollmer, Timothy L. |
| author_facet | Piquet, Amanda L. Corboy, John R. Vollmer, Timothy L. |
| author_sort | Piquet, Amanda L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8170321 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81703212021-06-07 Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Piquet, Amanda L. Corboy, John R. Vollmer, Timothy L. Ther Adv Neurol Disord Letter to the Editor SAGE Publications 2021-05-31 /pmc/articles/PMC8170321/ /pubmed/34104219 http://dx.doi.org/10.1177/17562864211019567 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Piquet, Amanda L. Corboy, John R. Vollmer, Timothy L. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title | Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| title_full | Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| title_fullStr | Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| title_full_unstemmed | Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| title_short | Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| title_sort | correspondence to: humoral immune response to covid-19 mrna vaccine in
patients with multiple sclerosis treated with high-efficacy disease-modifying
therapies |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170321/ https://www.ncbi.nlm.nih.gov/pubmed/34104219 http://dx.doi.org/10.1177/17562864211019567 |
| work_keys_str_mv | AT piquetamandal correspondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT corboyjohnr correspondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT vollmertimothyl correspondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies |